Core Viewpoint - Haemonetics Corporation is enhancing its market position through strategic acquisitions, specifically the acquisition of Vivasure Medical Limited, which will strengthen its capabilities in blood management solutions and structural heart procedures [1][3][6] Group 1: Company Overview - Haemonetics Corporation specializes in blood management solutions and is recognized for its innovative medical technology products [1] - The company faces competition in the medical technology sector but is actively working to strengthen its position through acquisitions and product development [1] Group 2: Acquisition Details - Haemonetics announced the acquisition of Vivasure Medical Limited for €100 million upfront, with potential milestone payments of up to €85 million [3] - The acquisition will be funded with cash on hand, indicating Haemonetics' financial strength [3][6] - Vivasure's PerQseal Elite system, which is designed for closing large-bore arterial and venous access sites, is a significant addition to Haemonetics' product offerings [4] Group 3: Product Impact - The PerQseal Elite system has received CE Mark approval in Europe and has a Premarket Approval application submitted to the U.S. FDA [5] - The system demonstrated a 0% major complication rate at thirty days in the ELITE arterial study, showcasing its effectiveness and ease of use [5] - This acquisition is expected to enhance Haemonetics' position in the cardiology sector, aligning with the growing demand for large-bore vascular access [4][5] Group 4: Market Performance - Barrington set a price target of $93 for Haemonetics, indicating a potential upside of 13.37% from its current trading price of $82.03 [2][6] - The stock has shown a recent decrease of 2.39%, with a trading range between $81.94 and $84.92 [2] - Over the past year, the stock has fluctuated between $47.32 and $87.32, indicating significant volatility [2]

Core Viewpoint - Haemonetics Corporation has announced the acquisition of Vivasure Medical Limited, enhancing its portfolio in the vessel closure market with innovative technology aimed at improving patient outcomes [1][4]. Acquisition Details - The acquisition involves an upfront cash payment of €100 million, approximately €52 million net after accounting for previous investments and loans, with potential additional contingent consideration of up to €85 million based on sales growth and milestone achievements [3]. - The transaction was financed through Haemonetics' available cash on hand [3]. Product Information - Vivasure's PerQseal Elite system utilizes a bioabsorbable patch for sealing large-bore arteriotomies and venotomies, providing a sutureless and fully absorbable solution for various medical procedures [2]. - The system has received CE Mark approval in Europe and a Premarket Approval application was submitted to the U.S. FDA in 2025 [2]. Strategic Implications - The acquisition is expected to expand Haemonetics' range of closure devices and strengthen its position in the growing structural heart and endovascular procedure markets [4]. - The clinical performance of the PerQseal Elite system, demonstrated by a 0% major complication rate at thirty-day follow-up, positions Haemonetics for increased leadership in advanced closure technologies [2][4]. Company Background - Haemonetics is a global medical technology company focused on improving healthcare quality and efficiency through innovative solutions [5]. - Vivasure Medical Limited specializes in advanced polymer implants and delivery systems for minimally invasive vessel closure [6].